Biodesix, Inc.

NasdaqGM:BDSX Stock Report

Market Cap: US$197.8m

Biodesix Management

Management criteria checks 3/4

Biodesix's CEO is Scott Hutton, appointed in Jan 2020, has a tenure of 4.92 years. total yearly compensation is $2.29M, comprised of 22.5% salary and 77.5% bonuses, including company stock and options. directly owns 0.37% of the company’s shares, worth $724.85K. The average tenure of the management team and the board of directors is 4.8 years and 4.9 years respectively.

Key information

Scott Hutton

Chief executive officer

US$2.3m

Total compensation

CEO salary percentage22.5%
CEO tenure4.9yrs
CEO ownership0.4%
Management average tenure4.8yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

With A 26% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Nov 21
With A 26% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?

Sep 24
Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?

Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

Jun 12
Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Mar 03
With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce

Jan 04
Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce

It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks

Jul 16
It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks

A Second Look At Biodesix

Oct 18

Biodesix expects Q3 revenue above the consensus

Oct 11

Biodesix GAAP EPS of -$0.40 beats by $0.07, revenue of $10.95M beats by $2.12M

Aug 04

Biodesix: Bad Diagnosis

May 26

Analysts' Revenue Estimates For Biodesix, Inc. (NASDAQ:BDSX) Are Surging Higher

Mar 15
Analysts' Revenue Estimates For Biodesix, Inc. (NASDAQ:BDSX) Are Surging Higher

CEO Compensation Analysis

How has Scott Hutton's remuneration changed compared to Biodesix's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$44m

Jun 30 2024n/an/a

-US$45m

Mar 31 2024n/an/a

-US$47m

Dec 31 2023US$2mUS$515k

-US$52m

Sep 30 2023n/an/a

-US$63m

Jun 30 2023n/an/a

-US$66m

Mar 31 2023n/an/a

-US$69m

Dec 31 2022US$3mUS$515k

-US$65m

Sep 30 2022n/an/a

-US$58m

Jun 30 2022n/an/a

-US$56m

Mar 31 2022n/an/a

-US$52m

Dec 31 2021US$5mUS$490k

-US$43m

Sep 30 2021n/an/a

-US$34m

Jun 30 2021n/an/a

-US$32m

Mar 31 2021n/an/a

-US$29m

Dec 31 2020US$2mUS$364k

-US$31m

Sep 30 2020n/an/a

-US$33m

Jun 30 2020n/an/a

-US$34m

Mar 31 2020n/an/a

-US$33m

Dec 31 2019US$337kUS$298k

-US$31m

Compensation vs Market: Scott's total compensation ($USD2.29M) is above average for companies of similar size in the US market ($USD1.44M).

Compensation vs Earnings: Scott's compensation has been consistent with company performance over the past year.

CEO

Scott Hutton (52 yo)

4.9yrs

Tenure

US$2,290,546

Compensation

Mr. Scott Hutton serves as President, Chief Executive Officer and Director at Biodesix, Inc. since January 1, 2020. He served as Chief Operating Officer at Biodesix, Inc. since March 2018 until December 20...

Leadership Team

NamePositionTenureCompensationOwnership
Scott Hutton
President4.9yrsUS$2.29m0.37%
$ 724.8k
Robin Cowie
CFO, Secretary & Treasurer7.7yrsUS$844.37k0.14%
$ 276.5k
Kieran O'Kane
Chief Commercial Officer6.8yrsUS$672.62k0.067%
$ 132.5k
Heinrich Röder
Founder & CTOno datano datano data
Jessica Olbricht
Senior Director of Human Resourcesless than a yearno datano data
Gary Pestano
Chief Development Officer6.2yrsno data0.087%
$ 172.8k
Bobbi Coffin
Chief Growth Officer4.8yrsno datano data
James Jett
Co-Chief Medical Officerno datano datano data
Steven Springmeyer
Co-Chief Medical Officer4.6yrsno datano data
Christopher Vazquez
VP & Controller3.8yrsno data0.0080%
$ 15.8k

4.8yrs

Average Tenure

49.5yo

Average Age

Experienced Management: BDSX's management team is considered experienced (4.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Scott Hutton
President4.9yrsUS$2.29m0.37%
$ 724.8k
John Patience
Independent Chairman16.5yrsUS$187.58k5.07%
$ 10.0m
Jack Schuler
Independent Director16.5yrsUS$187.58k21.44%
$ 42.4m
Hany Massarany
Independent Director4.4yrsUS$201.47k0.23%
$ 458.5k
Lair Kennedy
Independent Director1.9yrsUS$465.10k17.5%
$ 34.6m
Paul A. Bunn
Member of Scientific Advisory Boardno datano datano data
Matthew Strobeck
Independent Director12.9yrsUS$196.84k2.1%
$ 4.2m
John Kayyem
Independent Director3yrsUS$187.58k0.25%
$ 486.3k
David Carbone
Member of Scientific Advisory Boardno datano datano data
Craig Whitehouse
Member of Scientific Advisory Boardno datano datano data
Jean Franchi
Independent Director4.7yrsUS$206.10k0.056%
$ 111.2k
Charles Watts
Independent Director5.4yrsUS$187.58k0.26%
$ 510.0k

4.9yrs

Average Tenure

63yo

Average Age

Experienced Board: BDSX's board of directors are considered experienced (4.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 08:27
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biodesix, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sung Ji NamBTIG
Kyle MiksonCanaccord Genuity
William BonelloCraig-Hallum Capital Group LLC